United States News Todas as matérias

CervoMed (NASDAQ:CRVO) reported its financial results for the first quarter of 2026, alongside corporate and clinical milestones for its lead oral small-molecule drug candidate, neflamapimod.

Niu Technologies (NASDAQ:NIU), a leading provider of smart electric two-wheel vehicles, announced its unaudited financial results for the first quarter ended March 31, 2026.

WeRide (NASDAQ:WRD) reported that its mass-production driving solution achieved a record-breaking performance at the Hefei round of the Second China Urban Intelligent Driving Competition, marking a significant milestone for the company’s Level 2++ autonomous systems.

V2X (NYSE:VVX) has been awarded a contract by the U.S. Navy’s Naval Air Systems Command (NAVAIR) to support the Large Aircraft Infrared Countermeasures (LAIRCM) program.

Bitcoin Depot (NASDAQ:BTM) has filed for voluntary Chapter 11 bankruptcy protection to facilitate an orderly wind-down of its business and a sale of its corporate assets.

Philips (NYSE:PHG), in partnership with healthcare technology firms Cuviva and Vingmed, has been selected by Region Stockholm to implement a large-scale hospital-at-home program.

Edible Garden (NASDAQ:EDBL) reported strong top-line revenue growth for the first quarter of 2026, driven by retail expansion and broader consumer adoption of its product portfolio, even as heavy capital deployment for its beverage infrastructure weighed on near-term profitability.

Arrive AI (NASDAQ:ARAI), a company developing AI-powered autonomous vehicle and robotics solutions, announced its first-quarter 2026 financial results and provided an operational update.

RenX Enterprises (NASDAQ:RENX) reported strong sequential revenue expansion for the first quarter of 2026, driven by higher utilization across its contracted hauling agreements and accelerating bulk material sales, even as advanced technology integration costs left consolidated bottom-line metrics in a deficit.

Creative Realities (NASDAQ:CREX) reported a significant increase in top-line revenue for the first quarter of fiscal 2026, driven primarily by the financial integration of its Cineplex Digital Media acquisition, even as margin compression and one-time structural charges pulled bottom-line metrics into a deficit.

Palvella Therapeutics (NASDAQ:PVLA) reported positive clinical data from its Phase 2 TOIVA trial evaluating its proprietary topical formulation of rapamycin, detailing significant therapeutic benefits for patients suffering from rare vascular skin disorders.

RBC Bearings Incorporated (NYSE:RBC) reported strong financial results for the fourth quarter of fiscal 2026, beating Wall Street expectations as accelerating production rates across commercial aviation and defense programs catalyzed top-line growth.

MiNK Therapeutics (NASDAQ:INKT) reported its first-quarter 2026 financial results and operational milestones, highlighting clinical advancement within its invariant natural killer T (iNKT) cell platform alongside successful balance sheet deleveraging.

Digi Power X (NASDAQ:DGXX) reported a wider net loss for the first quarter of 2026, reflecting the financial impacts of its ongoing structural transition away from legacy business operations and toward high-density artificial intelligence infrastructure.

Immuneering (NASDAQ:IMRX), a clinical-stage oncology company developing innovative medicines targeting the MAPK pathway, reported its first-quarter 2026 financial results and provided a corporate update.

BioXcel Therapeutics (NASDAQ:BTAI) announced that the U.S. Food and Drug Administration has formally accepted a supplemental New Drug Application for its lead neuropsychiatric drug, providing a clear regulatory catalyst as the company manages tightening capital constraints.

Traws Pharma (NASDAQ:TRAW) reported a net loss for the first quarter of 2026 as the company aggressively scaled up investments in its respiratory antiviral pipeline, pivoting away from the profitable metrics recorded in the prior year's opening period.

Protara Therapeutics (NASDAQ:TARA) reported updated 12-month interim data from the Cohort A arm of its Phase 2 ADVANCED-2 clinical trial, demonstrating sustained tumor clearance and a favorable safety profile for its lead oncology candidate.

PowerBank (NASDAQ:SUUN) reported a significant expansion in its underlying profit margins and a strengthened balance sheet for the first nine months of fiscal year 2026, driven by systematic execution of its North American clean energy project pipeline.

Indaptus Therapeutics (NASDAQ:INDP) announced a sweeping re-evaluation of its core developmental pipeline and resource allocation alongside a significant leadership transition, signaling a strategic pivot as the company faces tightening liquidity constraints.

Purple Biotech (NASDAQ:PPBT) reported its financial and operational results for the first quarter of 2026, highlighting clinical milestones within its immunotherapy pipeline and a stabilized bottom line supported by non-operating income.

The Board of Directors of Genco Shipping & Trading (NYSE:GNK) has unanimously rejected an unsolicited tender offer from Diana Shipping to acquire all outstanding shares of the company for $23.50 per share in cash, setting up a high-stakes corporate standoff in the global maritime sector.

Tenaya Therapeutics (NASDAQ:TNYA), a clinical-stage biotechnology company developing gene therapies for heart disease, reported positive interim data from the first two cohorts of its ongoing RIDGE-1 Phase 1b/2 trial of TN-401 in patients with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

H World Group (NASDAQ:HTHT) reported double-digit revenue and turnover growth for the first quarter of 2026, capitalizating on persistent leisure and business travel demand across its sprawling multi-brand hospitality network.